Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy.
Body composition
Bone
GH replacement therapy
Growth hormone deficiency
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
19
02
2021
accepted:
20
07
2021
pubmed:
1
8
2021
medline:
23
11
2021
entrez:
31
7
2021
Statut:
ppublish
Résumé
The effects of growth hormone (GH) replacement on bone mass and body composition in adult with GH deficiency (AGHD) are still debated with regard to their persistence in the long term. Moreover, the impact of the gender on the response to GH is controversial. Aim of this study was to evaluate the long-term effects of rhGH replacement on bone mass and body composition in a monocentric cohort of patients with AGHD. Data from 118 patients with AGHD (34.8 ± 14.4 years, 43 women and 75 men) treated with rhGH for a period of at least 3 years up to a maximum of 10 were retrospectively collected. Bone mineral density (BMD) at the lumbar spine, femur, and 1/3 radius, and total and truncular body composition were evaluated by dual-energy X-ray absorption (DXA) before and during treatment. Clinical and laboratory evaluations were performed before and during the treatment period on an annual basis. Lumbar spine BMD consistently increased in males, while it decreased in females after a transient improvement observed during the first 4 years of therapy. There were no significant changes in femoral and 1/3 radial BMD in either sexes. Lean mass significantly increased in both sexes, while fat mass only decreased in males. In AGHD patients long-term rhGH replacement therapy induces a positive effect with regard to bone mass and body composition. A sexual dimorphism in the response to treatment is evident, with males displaying a more favorable outcome.
Identifiants
pubmed: 34331234
doi: 10.1007/s12020-021-02835-6
pii: 10.1007/s12020-021-02835-6
doi:
Substances chimiques
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
666-675Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
K.K. Ho, Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157, 695e700 (2007)
doi: 10.1530/EJE-07-0631
S.J. Holmes, G. Economou, R.W. Whitehouse et al. Reduced bone mineral density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 78, 669e74 (1994)
B. Angelin, M. Rudling, Growth hormone and lipoprotein metabolism. Endocrinol Metab 2, 25–28 (1995)
D.A. Fryburg, R.A. Gelfand, E.J. Barrett, Growth hormone acutely stimulates muscle protein synthesis in normal humans. Am J Physiol 260, E 499–E 504 (1991)
D.M. Hoffman, R. Pallasser, M. Duncan et al. How is whole body protein turnover perturbed in growth hormone deficient adults? J Clin Endocrinol Metab 83, 4344–4349 (1998)
pubmed: 9851775
N.A. Tritos, Focus on growth hormone deficiency and bone in adults. Best Pract Res Clin Endocrinol Metab 31, 49–57 (2017)
doi: 10.1016/j.beem.2017.02.002
G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine. 52, 103–110 (2016)
doi: 10.1007/s12020-015-0738-z
J. Isgaard, M. Arcopinto, K. Karason, A. Cittadini, GH and the cardiovascular system: an update on a topic at heart. Endocrine 48, 25–35 (2015)
doi: 10.1007/s12020-014-0327-6
D. Mo, M. Fleseriu, R. Qi, N. Jia, C.J. Child, R. Bouillon, D.S. Hardin, Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3, 331–338 (2015)
doi: 10.1016/S2213-8587(15)00098-4
P. Chanson, The heart in growth hormone (GH) deficiency and the cardiovascular effects of GH. Ann Endocrinol S0003-4266, 30040–30048 (2020). Online ahead of print
C. Franco, J. Koranyi, J. Brandberg, L. Löon, B.K. Bengtsson, J. Svensson, G. Johannsson, The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen deficient women. Growth Horm IGF Res 19, 112–120 (2009)
doi: 10.1016/j.ghir.2008.07.001
P. Burman, A.G. Johansson, A. Siegbahn, B. Vessby, F.A. Karlsson, Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82, 550–555 (1997). https://doi.org/10.1210/jcem.82.2.3776
doi: 10.1210/jcem.82.2.3776
pubmed: 9024252
A. Mukherjee, J.E. Adams, L. Smethurst, S.M. Shalet, Interdependence of lean body mass and total body water, but not quality of life measures, during low dose GH replacement in GH-deficient adults. Eur J Endocrinol 153, 661–668 (2005). https://doi.org/10.1530/eje.1.02017
doi: 10.1530/eje.1.02017
pubmed: 16260424
P. Maison, P. Chanson, Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648–2652 (2003)
doi: 10.1161/01.CIR.0000100720.01867.1D
A. Ziagaki, D. Blaschke, W. Haverkamp, U. Plöckinger, Long-term growth hormone (GH) replacement of adult GH deficiency (GHD) benefits the heart. Eur J Endocrinol 181(Jul 1), 79–91 (2019)
doi: 10.1530/EJE-19-0132
N.M. Appelman-Dijkstra, K.M. Claessen, N.A. Hamdy et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol 81, 727e35 (2014)
doi: 10.1111/cen.12493
M. Barake, A. Klibanski, N.A. Tritos, Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99, 852e60 (2014)
doi: 10.1210/jc.2013-3921
A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12(2), 163–172 (2000)
doi: 10.1385/ENDO:12:2:163
P. Davidson, R. Milne, D. Chase et al. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol 60, 92e8 (2004)
doi: 10.1111/j.1365-2265.2004.01935.x
M. Elbornsson, G. Gotherstrom, I. Bosaeus et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166, 787–795 (2012)
doi: 10.1530/EJE-11-1072
M. Elbornsson, G. Gotherstrom, I. Bosæus, B.A. Bengtsson, G. Johannsson, J. Svensson, Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 168, 745–753 (2013)
doi: 10.1530/EJE-12-1083
A. Rossini, R. Lanzi, M. Losa et al. Predictors of bone responsiveness to growth hormone (GH) replacement in adult GH-deficient patients. Calcif Tissue Int 88, 304–313 (2011)
doi: 10.1007/s00223-010-9459-8
G. Götherström, B.A. Bengtsson, I. Bosaeus, G. Johannsson, J. Svensson, G.H. Ten-year, replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 156, 55–64 (2007)
doi: 10.1530/eje.1.02317
N.A. Tritos, A.H. Hamrahian, D. King, S.L. Greenspan, D.M. Cook, P.J. Jönsson, M. Koltowska-Häggstrom, B.M. Biller, Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency – a KIMS database analysis. Clin Endocrinol 79, 178–184 (2013)
doi: 10.1111/cen.12132
G. Corneli, C. Di Somma, R. Baldelli et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153(2), 257–264 (2005)
doi: 10.1530/eje.1.01967
S. Baim, N. Binkley, J.P. Bilezikian, D.L. Kendler, D.B. Hans, E.M. Lewiecki, S. Silverman, Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 11, 75–791 (2008)
doi: 10.1016/j.jocd.2007.12.007
Y.M. Cheung, G. Roff, M. Grossmann, Precision of the hologic horizon A dual energy X-ray absorptiometry in the assessment of body composition. Obes Res Clin Pract. 14, 514–518 (2020). https://doi.org/10.1016/j.orcp.2020.10.005 . Epub 2020 Oct 31. PMID: 33132075
doi: 10.1016/j.orcp.2020.10.005
pubmed: 33132075
M.L. Bouxsein, R. Eastell, L.Y. Lui, L.A. Wu, A.E. de Papp, A. Grauer, F. Marin, J.A. Cauley, D.C. Bauer, D.M. Black, FNIH Bone Quality Project. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34, 632–642 (2019). https://doi.org/10.1002/jbmr.3641
doi: 10.1002/jbmr.3641
pubmed: 30674078
G. Gotherstrom, J. Svensson, J. Koranyi, M. Alpsten, I. Bosaeus, B. Bengtsson, G. Johannsson, A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86, 4657–4665 (2001)
doi: 10.1210/jcem.86.10.7887
S. Yuan, Z.H. Wan, S.L. Cheng, K. Michaëlsson, S.C. Larsson, Insulin-like growth factor-1, bone mineral density, and fracture: a mendelian randomization study. J Clin Endocrinol Metab 106, e1552–e1558 (2021). https://doi.org/10.1210/clinem/dgaa963
doi: 10.1210/clinem/dgaa963
pubmed: 33462619
pmcid: 7993594
R. Lanzi, M. Losa, I. Villa, E. Gatti, M. Sirtori, F.C. Dal, A. Rubinacci, GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. Eur J Endocrinol 148, 185–191 (2003)
doi: 10.1530/eje.0.1480185
E. Mrak, I. Villa, R. Lanzi, M. Losa, F. Guidobono, A. Rubinacci, Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. J Endocrinol 192, 639–645 (2007)
doi: 10.1677/joe.1.07073
B. Abrahamsen, J. Hangaard, H.C. Horn, T.B. Hansen, G. Gregersen, M. Hansen- Nord, N. Vahl, P. Junker, M. Andersen, C. Hagen, Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol 57, 273–281 (2002)
doi: 10.1046/j.1365-2265.2002.01582.x
E.H. Oldfield, J.A. Jane Jr, M.O. Thorner, C.L. Pledger, J.P. Sheehan, M.L. Vance, Correlation between GH and IGF-1 during treatment for acromegaly. J Neurosurg 126, 1959–1966 (2017). https://doi.org/10.3171/2016.8.JNS161123
doi: 10.3171/2016.8.JNS161123
pubmed: 27858572
Z. Pekkolay, F. Kılınç, N. Gozel, E. Önalan, A.K. Tuzcu, Increased serum sclerostin levels in patients with active Acromegaly. J Clin Endocrinol Metab 105, dgz254 (2020)
doi: 10.1210/clinem/dgz254
M.R. Laurent, V. Dubois, F. Claessens, S.M.P. Verschueren, D. Vanderschueren, E. Gielen, F. Jardí, Muscle-bone interactions: From experimental models to the clinic? A critical update. Mol Cell Endocrinol 432, 14e36 (2016)
doi: 10.1016/j.mce.2015.10.017
H. Kaji, Effects of myokines on bone. Bonekey Rep 826, 1038–1044 (2016)
J. Koranyi, I. Bosaeus, M. Alpsten, B.A. Bengtsson, G. Johannsson, Body composition during GH replacement in adults - methodological variations with respect to gender. Eur J Endocrinol 154, 545–553 (2006). https://doi.org/10.1530/eje.1.02118
doi: 10.1530/eje.1.02118
pubmed: 16556717
M.R. Postma, A.P. van Beek, P.J. Jönsson, C.C. van Bunderen, M.L. Drent, A.F. Mattsson, C. Camacho-Hubner, Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls. Neuroendocrinology 109(2), 131–140 (2019)
doi: 10.1159/000499430
V. Birzniece, K.K. Ho, Sex steroids and the GH axis: implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metabol 31, 59–69 (2017)
doi: 10.1016/j.beem.2017.03.003
J. Gibney, T. Wolthers, G. Johannsson, A.M. Umpleby, K.K. Ho, Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289, E266–E271 (2005)
doi: 10.1152/ajpendo.00483.2004
S.L. Bonnick, HSA: beyond BMD with DXA. Bone 41, S9–S12 (2007)
pubmed: 17459802
D. Bikle, S. Majumdar, A. Laib, L. Powell-Braxton, C. Rosen, W. Beamer, E. Nauman, C. Leary, B. Halloran, The skeletal structure of insulin-like growth factor I-deficient mice. J Bone Miner Res 16, 2320–2329 (2001)
doi: 10.1359/jbmr.2001.16.12.2320
G. Zhao, M.C. Monier-Faugere, M.C. Langub, Z. Geng, T. Nakayama, J.W. Pike, S.D. Chernausek, C.J. Rosen, L.R. Donahue, H.H. Malluche, J.A. Fagin, T.L. Clemens, Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 141, 2674–2682 (2000)
doi: 10.1210/endo.141.7.7585
K.M. Claessen, N.M. Appelman-Dijkstra, D.M. Adoptie, F. Roelfsema, J.W. Smit, N.R. Biermasz, A.M. Pereira, Metabolic profile in growth hormone- deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 98(1), 352–361 (2013)
doi: 10.1210/jc.2012-2940